Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Heron Therapeutics Inc's Business Segments
Heron Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 38
Regions Reported
-
Revenue by Product & Service Category -
- CINVANTI57.9%
- ZYNRELEF29.4%
- APONVIE11.4%
- SUSTOL1.4%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| CINVANTI | $ 22 | 57.9% |
| ZYNRELEF | $ 11 | 29.4% |
| APONVIE | $ 4 | 11.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Heron Therapeutics Inc dataset.
Description of Heron Therapeutics Inc's Business Segments
Heron Therapeutics Inc. is a pharmaceutical company that is focused on the development and commercialization of innovative therapies to address unmet medical needs. The company is dedicated to providing patients with safe and effective alternatives to existing treatments that do not adequately address their conditions or that may be associated with undesirable side effects.
Heron Therapeutics was founded in 1983 and is based in San Diego, California. The company operates under the leadership of CEO Barry Quart, who has been with the company since 2000. The company has a team of over 300 employees who work tirelessly to develop new and innovative treatments that improve patient outcomes.
Heron Therapeutics has developed a proprietary drug delivery system called Sustained Release (SR) technology, which is used to develop long-acting formulations of existing drugs. The technology allows for drugs to be released over an extended period, which can eliminate the need for multiple dosing throughout the day. SR technology has been used to develop numerous products in the Heron pipeline, including Zynrelef (bupivacaine and meloxicam), a recently FDA-approved drug for postoperative pain management.
Heron Therapeutics focuses on developing products for pain management, cancer supportive care, and rare diseases. The company's lead product candidate, HTX-011, is a novel local anesthetic that is being developed for postoperative pain management. The drug, which is administered during surgery, has been shown to provide superior pain relief compared to existing therapies and may reduce the need for opioids to manage postoperative pain.
In addition to its research and development efforts, Heron Therapeutics has a focus on commercialization. The company has a dedicated sales and marketing team that is responsible for launching new products and promoting existing products to healthcare professionals.
Overall, Heron Therapeutics is a biotechnology company that is dedicated to advancing medical treatments for unmet medical needs. With a focus on innovation, research and development, and commercialization, the company is well-positioned for continued growth and success in the industry.
Heron Therapeutics was founded in 1983 and is based in San Diego, California. The company operates under the leadership of CEO Barry Quart, who has been with the company since 2000. The company has a team of over 300 employees who work tirelessly to develop new and innovative treatments that improve patient outcomes.
Heron Therapeutics has developed a proprietary drug delivery system called Sustained Release (SR) technology, which is used to develop long-acting formulations of existing drugs. The technology allows for drugs to be released over an extended period, which can eliminate the need for multiple dosing throughout the day. SR technology has been used to develop numerous products in the Heron pipeline, including Zynrelef (bupivacaine and meloxicam), a recently FDA-approved drug for postoperative pain management.
Heron Therapeutics focuses on developing products for pain management, cancer supportive care, and rare diseases. The company's lead product candidate, HTX-011, is a novel local anesthetic that is being developed for postoperative pain management. The drug, which is administered during surgery, has been shown to provide superior pain relief compared to existing therapies and may reduce the need for opioids to manage postoperative pain.
In addition to its research and development efforts, Heron Therapeutics has a focus on commercialization. The company has a dedicated sales and marketing team that is responsible for launching new products and promoting existing products to healthcare professionals.
Overall, Heron Therapeutics is a biotechnology company that is dedicated to advancing medical treatments for unmet medical needs. With a focus on innovation, research and development, and commercialization, the company is well-positioned for continued growth and success in the industry.
Heron Therapeutics Inc is a biotechnology firm focused on addressing unmet medical needs through the development and commercialization of innovative pharmaceutical products. The companys main operational segment is pharmaceuticals, emphasizing both branded and generic medications aimed at optimizing patient care and enhancing treatment outcomes particularly in areas such as pain management, postoperative care, and supportive care for cancer patients.
Segments:
Pharmaceuticals:
Heron Therapeutics operates primarily within the pharmaceuticals segment, engaged in the research, manufacture, and marketing of treatments that cater to various medical needs. This includes medications designed specifically for pain management, therapies for nausea and vomiting related to chemotherapy, and specialized treatments targeting the aftermath of surgical procedures.
Products:
1. SUSTOL (granisetron) Injection:
- Indication: SUSTOL is a long-acting 5-HT3 receptor antagonist designed for the prevention of both acute and delayed nausea and vomiting that often arise as side effects of chemotherapy. Its sustained-release formulation allows for effective dosing in the management of chemotherapy-induced nausea and vomiting (CINV), ensuring patient comfort and adherence to treatment protocols.
2. CINVANTI (aprepitant) Injectable Emulsion:
- Indication: CINVANTI is formulated as an intravenous emulsion of aprepitant, which acts as a neurokinin-1 receptor antagonist. This product is critical in the prevention of CINV, particularly in patients receiving highly emetogenic chemotherapy regimens, contributing significantly to improved quality of life during cancer treatment.
3. HTX-011:
- Indication: This is a long-acting local anesthetic that combines the properties of bupivacaine and meloxicam, designed specifically for postoperative pain management. HTX-011 aims to provide targeted pain relief lasting up to 72 hours, significantly reducing the need for opioid medications and the associated risk of addiction and side effects. Through its innovative delivery system, HTX-011 can improve recovery times and patient satisfaction post-surgery.
4. ZYNRELEF (bupivacaine and meloxicam) Injection:
- Indication: ZYNRELEF is a unique dual-acting agent that combines a local anesthetic (bupivacaine) with a nonsteroidal anti-inflammatory drug (NSAID) (meloxicam). It is indicated for the management of postoperative pain and is notable for offering both immediate and prolonged analgesic effects. This product represents a strategic approach to multimodal pain management, integrating both local anesthesia and anti-inflammatory mechanisms.
5. Spherusol:
- Application: Spherusol is a diagnostic skin test utilized to identify delayed-type hypersensitivity reactions to coccidioidomycosis, also known as Valley fever. This test plays a crucial role in diagnosing patients who may be suffering from this fungal infection, assisting healthcare providers in making informed treatment decisions.
Services:
Heron Therapeutics Inc also emphasizes comprehensive support services aimed at facilitating the use of their products and improving overall patient experiences. The company offers the following services:
1. Patient Assistance Programs:
- Heron provides financial assistance avenues for eligible patients to ensure they can afford necessary medications, thus fostering better adherence to treatment and improving health outcomes.
2. Reimbursement Support:
- The company aids healthcare providers and patients in navigating the complex reimbursement landscape for their products, enhancing accessibility and streamlining the process of obtaining necessary treatments.
3. Educational Resources:
- Recognizing the importance of informed healthcare choices, Heron Therapeutics produces comprehensive educational materials and programs tailored for both healthcare professionals and patients. These resources focus on the safe and effective use of their products, aiming to elevate awareness and understanding of treatment options.
4. Clinical Trial Programs:
- To support ongoing innovation and expand therapeutic options, Heron is involved in various clinical research initiatives. These programs aim to investigate new pharmaceutical agents and refine treatment strategies in pain management, postoperative care, and supportive care for cancer patients.
In summary, Heron Therapeutics Inc stands as a pivotal player in the biotechnology sector, delivering specialized pharmaceutical products and essential services that meet the critical needs of patients and healthcare providers alike. Through their extensive portfolio and comprehensive support offerings, they contribute significantly to enhancing patient care in pain management and related therapeutic areas.
Segments:
Pharmaceuticals:
Heron Therapeutics operates primarily within the pharmaceuticals segment, engaged in the research, manufacture, and marketing of treatments that cater to various medical needs. This includes medications designed specifically for pain management, therapies for nausea and vomiting related to chemotherapy, and specialized treatments targeting the aftermath of surgical procedures.
Products:
1. SUSTOL (granisetron) Injection:
- Indication: SUSTOL is a long-acting 5-HT3 receptor antagonist designed for the prevention of both acute and delayed nausea and vomiting that often arise as side effects of chemotherapy. Its sustained-release formulation allows for effective dosing in the management of chemotherapy-induced nausea and vomiting (CINV), ensuring patient comfort and adherence to treatment protocols.
2. CINVANTI (aprepitant) Injectable Emulsion:
- Indication: CINVANTI is formulated as an intravenous emulsion of aprepitant, which acts as a neurokinin-1 receptor antagonist. This product is critical in the prevention of CINV, particularly in patients receiving highly emetogenic chemotherapy regimens, contributing significantly to improved quality of life during cancer treatment.
3. HTX-011:
- Indication: This is a long-acting local anesthetic that combines the properties of bupivacaine and meloxicam, designed specifically for postoperative pain management. HTX-011 aims to provide targeted pain relief lasting up to 72 hours, significantly reducing the need for opioid medications and the associated risk of addiction and side effects. Through its innovative delivery system, HTX-011 can improve recovery times and patient satisfaction post-surgery.
4. ZYNRELEF (bupivacaine and meloxicam) Injection:
- Indication: ZYNRELEF is a unique dual-acting agent that combines a local anesthetic (bupivacaine) with a nonsteroidal anti-inflammatory drug (NSAID) (meloxicam). It is indicated for the management of postoperative pain and is notable for offering both immediate and prolonged analgesic effects. This product represents a strategic approach to multimodal pain management, integrating both local anesthesia and anti-inflammatory mechanisms.
5. Spherusol:
- Application: Spherusol is a diagnostic skin test utilized to identify delayed-type hypersensitivity reactions to coccidioidomycosis, also known as Valley fever. This test plays a crucial role in diagnosing patients who may be suffering from this fungal infection, assisting healthcare providers in making informed treatment decisions.
Services:
Heron Therapeutics Inc also emphasizes comprehensive support services aimed at facilitating the use of their products and improving overall patient experiences. The company offers the following services:
1. Patient Assistance Programs:
- Heron provides financial assistance avenues for eligible patients to ensure they can afford necessary medications, thus fostering better adherence to treatment and improving health outcomes.
2. Reimbursement Support:
- The company aids healthcare providers and patients in navigating the complex reimbursement landscape for their products, enhancing accessibility and streamlining the process of obtaining necessary treatments.
3. Educational Resources:
- Recognizing the importance of informed healthcare choices, Heron Therapeutics produces comprehensive educational materials and programs tailored for both healthcare professionals and patients. These resources focus on the safe and effective use of their products, aiming to elevate awareness and understanding of treatment options.
4. Clinical Trial Programs:
- To support ongoing innovation and expand therapeutic options, Heron is involved in various clinical research initiatives. These programs aim to investigate new pharmaceutical agents and refine treatment strategies in pain management, postoperative care, and supportive care for cancer patients.
In summary, Heron Therapeutics Inc stands as a pivotal player in the biotechnology sector, delivering specialized pharmaceutical products and essential services that meet the critical needs of patients and healthcare providers alike. Through their extensive portfolio and comprehensive support offerings, they contribute significantly to enhancing patient care in pain management and related therapeutic areas.